Home » Stocks » Immunovant

Immunovant, Inc. (IMVT)

Stock Price: $42.02 USD 1.99 (4.96%)
Updated Oct 22, 2020 1:51 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.66B
Revenue (ttm) n/a
Net Income (ttm) -58.43M
Shares Out 87.08M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $42.02
Previous Close $40.03
Change ($) 1.99
Change (%) 4.96%
Day's Open 40.39
Day's Range 39.58 - 42.10
Day's Volume 86,877
52-Week Range 8.34 - 43.94

More Stats

Market Cap 3.66B
Enterprise Value 3.38B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 87.08M
Float 36.78M
EPS (basic) -1.18
EPS (diluted) -1.18
FCF / Share -0.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.37M
Short Ratio 3.13
Short % of Float 6.45%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 15.21
Revenue n/a
Operating Income -58.53M
Net Income -58.43M
Free Cash Flow -66.98M
Net Cash 276.21M
Net Cash / Share 3.17
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -29.32%
ROE -57.14%
ROIC -250.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 8
Overweight 2
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(13.29% upside)
Current: $42.02
Target: 47.60
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-66.08-28.43
Net Income-66.39-28.60
Shares Outstanding43.2022.17
Earnings Per Share-1.54-1.29
Operating Cash Flow-53.36-28.55
Capital Expenditures-0.03-0.05
Free Cash Flow-53.39-28.60
Cash & Equivalents1016.99
Net Cash / Debt1016.99
Book Value94.077.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunovant, Inc.
Country United States
Employees 51
CEO Peter Salzmann

Stock Information

Ticker Symbol IMVT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMVT


Immunovant, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.